176 related articles for article (PubMed ID: 19115932)
1. rAAV/Her-2/neu loading of dendritic cells for a potent cellular-mediated MHC class I restricted immune response against ovarian cancer.
Yu Y; Pilgrim P; Zhou W; Gagliano N; Frezza EE; Jenkins M; Weidanz JA; Lustgarten J; Cannon M; Bumm K; Cobos E; Kast WM; Chiriva-Internati M
Viral Immunol; 2008 Dec; 21(4):435-42. PubMed ID: 19115932
[TBL] [Abstract][Full Text] [Related]
2. Protective CD8+ T-cell responses to cytomegalovirus driven by rAAV/GFP/IE1 loading of dendritic cells.
Yu Y; Pilgrim P; Yan J; Zhou W; Jenkins M; Gagliano N; Bumm K; Cannon M; Milzani A; Dalle-Donne I; Kast WM; Cobos E; Chiriva-Internati M
J Transl Med; 2008 Oct; 6():56. PubMed ID: 18834548
[TBL] [Abstract][Full Text] [Related]
3. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes.
Brossart P; Stuhler G; Flad T; Stevanovic S; Rammensee HG; Kanz L; Brugger W
Cancer Res; 1998 Feb; 58(4):732-6. PubMed ID: 9485028
[TBL] [Abstract][Full Text] [Related]
4. Use and specificity of breast cancer antigen/milk protein BA46 for generating anti-self-cytotoxic T lymphocytes by recombinant adeno-associated virus-based gene loading of dendritic cells.
Liu Y; Chiriva-Internati M; You C; Luo R; You H; Prasad CK; Grizzi F; Cobos E; Klimberg VS; Kay H; Mehta JL; Hermonat PL
Cancer Gene Ther; 2005 Mar; 12(3):304-12. PubMed ID: 15565181
[TBL] [Abstract][Full Text] [Related]
5. HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1-restricted cytotoxic T lymphocytes.
Seliger B; Rongcun Y; Atkins D; Hammers S; Huber C; Störkel S; Kiessling R
Int J Cancer; 2000 Aug; 87(3):349-59. PubMed ID: 10897039
[TBL] [Abstract][Full Text] [Related]
6. Testing recombinant adeno-associated virus-gene loading of dendritic cells for generating potent cytotoxic T lymphocytes against a prototype self-antigen, multiple myeloma HM1.24.
Chiriva-Internati M; Liu Y; Weidanz JA; Grizzi F; You H; Zhou W; Bumm K; Barlogie B; Mehta JL; Hermonat PL
Blood; 2003 Nov; 102(9):3100-7. PubMed ID: 12855576
[TBL] [Abstract][Full Text] [Related]
7. Activation of tumor antigen-specific cytotoxic T lymphocytes (CTLs) by human dendritic cells infected with an attenuated influenza A virus expressing a CTL epitope derived from the HER-2/neu proto-oncogene.
Efferson CL; Schickli J; Ko BK; Kawano K; Mouzi S; Palese P; García-Sastre A; Ioannides CG
J Virol; 2003 Jul; 77(13):7411-24. PubMed ID: 12805440
[TBL] [Abstract][Full Text] [Related]
8. Natural CD8+ T-cell responses against MHC class I epitopes of the HER-2/ neu oncoprotein in patients with epithelial tumors.
Sotiropoulou PA; Perez SA; Voelter V; Echner H; Missitzis I; Tsavaris NB; Papamichail M; Baxevanis CN
Cancer Immunol Immunother; 2003 Dec; 52(12):771-9. PubMed ID: 13680193
[TBL] [Abstract][Full Text] [Related]
9. [rAAV/BA46-transfected dendritic cells can induce specific cellular immunity].
You CX; Su J; Liao WJ; Zhang JY; Liu Y; Paul LH; Luo RC
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Dec; 28(12):2146-9. PubMed ID: 19114342
[TBL] [Abstract][Full Text] [Related]
10. Rapid induction of cytotoxic T-cell response against cervical cancer cells by human papillomavirus type 16 E6 antigen gene delivery into human dendritic cells by an adeno-associated virus vector.
Liu Y; Chiriva-Internati M; Grizzi F; Salati E; Roman JJ; Lim S; Hermonat PL
Cancer Gene Ther; 2001 Dec; 8(12):948-57. PubMed ID: 11781657
[TBL] [Abstract][Full Text] [Related]
11. [Changes in immune function of dendritic cells infected by recombinant adenovirus containing Her2/neu gene of extracellular and transmembrane domain proteins].
Ma SD; Luo RC; Ding ZH; Lu F; Yuan CQ
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Aug; 26(8):1184-7. PubMed ID: 16939917
[TBL] [Abstract][Full Text] [Related]
12. Stimulation of human T cells by an influenza A vector expressing a CTL epitope from the HER-2/neu protooncogene results in higher numbers of antigen-specific TCRhi cells than stimulation with peptide. Divergent roles of IL-2 and IL-15.
Efferson CL; Kawano K; Tsuda N; Palese P; García-Sastre A; Ioannides CG
Anticancer Res; 2005; 25(2A):715-24. PubMed ID: 15868901
[TBL] [Abstract][Full Text] [Related]
13. Generation of populations of antigen-specific cytotoxic T cells using DCs transfected with DNA construct encoding HER2/neu tumor antigen epitopes.
Kuznetsova M; Lopatnikova J; Khantakova J; Maksyutov R; Maksyutov A; Sennikov S
BMC Immunol; 2017 Jun; 18(1):31. PubMed ID: 28633645
[TBL] [Abstract][Full Text] [Related]
14. Improvement of the cytotoxic T lymphocyte response against hepatocellular carcinoma by transduction of cancer cells with an adeno-associated virus carrying the interferon-γ gene.
Zhou J; Ma P; Li J; Cui X; Song W
Mol Med Rep; 2016 Apr; 13(4):3197-205. PubMed ID: 26936017
[TBL] [Abstract][Full Text] [Related]
15. HER-2/neu-derived peptide epitopes are also recognized by cytotoxic CD3(+)CD56(+) (natural killer T) lymphocytes.
Baxevanis CN; Gritzapis AD; Tsitsilonis OE; Katsoulas HL; Papamichail M
Int J Cancer; 2002 Apr; 98(6):864-72. PubMed ID: 11948464
[TBL] [Abstract][Full Text] [Related]
16. Enhanced HER-2/neu-specific antitumor immunity by cotransduction of mouse dendritic cells with two genes encoding HER-2/neu and alpha tumor necrosis factor.
Chen Z; Huang H; Chang T; Carlsen S; Saxena A; Marr R; Xing Z; Xiang J
Cancer Gene Ther; 2002 Sep; 9(9):778-86. PubMed ID: 12189528
[TBL] [Abstract][Full Text] [Related]
17. Potent CD4+ T-cell epitope P30 enhances HER2/neu-engineered dendritic cell-induced immunity against Tg1-1 breast cancer in transgenic FVBneuN mice by enhanced CD4+ T-cell-stimulated CTL responses.
Xie Y; Chen Y; Ahmed KA; Li W; Ahmed S; Sami A; Chibbar R; Tang X; Tao M; Xu J; Xiang J
Cancer Gene Ther; 2013 Oct; 20(10):590-8. PubMed ID: 24052129
[TBL] [Abstract][Full Text] [Related]
18. Vaccination with human HER-2/neu (435-443) CTL peptide induces effective antitumor immunity against HER-2/neu-expressing tumor cells in vivo.
Gritzapis AD; Mahaira LG; Perez SA; Cacoullos NT; Papamichail M; Baxevanis CN
Cancer Res; 2006 May; 66(10):5452-60. PubMed ID: 16707474
[TBL] [Abstract][Full Text] [Related]
19. Cytotoxicity of cord blood derived Her2/neu-specific cytotoxic T lymphocytes against human breast cancer in vitro and in vivo.
Wang P; Munger CM; Joshi AD; Pirruccello SJ; Joshi SS
Breast Cancer Res Treat; 2004 Jan; 83(1):15-23. PubMed ID: 14997051
[TBL] [Abstract][Full Text] [Related]
20. Identification of HLA-A3-restricted cytotoxic T lymphocyte epitopes from carcinoembryonic antigen and HER-2/neu by primary in vitro immunization with peptide-pulsed dendritic cells.
Kawashima I; Tsai V; Southwood S; Takesako K; Sette A; Celis E
Cancer Res; 1999 Jan; 59(2):431-5. PubMed ID: 9927058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
